Merck & Co., Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0000310158

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltBuy & Hold how tags are computed

Q2 2026 · 13 positions · Total reported value $526.41M · Top-10 concentration 99.8% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +7.0% · vs SPY +4.9% · Prev Value $526.41M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +7.4% · vs SPY +5.2% · Latest Value $820.35M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Merck & Co., Inc. disclosed 13 equity positions with a combined reported value of $526.41M. The filing implies a focused portfolio: its ten largest positions account for 99.8% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q2 2026 were PSNL ($188.20M), MRNA ($161.64M), KYMR ($88.54M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Merck & Co., Inc. opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 93% of names.

Of the 1 positions fully exited versus the prior quarter, the largest were CARM ($47.88K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • CARM CARISMA THERAPEUTICS INC · prev qtr: $47.88K

Insider Transactions (Form 4)

Latest Merck & Co., Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Merck & Co., Inc. is an SEC-registered 13F filer. As of Q2 2026 it reported 13 US equity positions with a combined value of $526.41M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 13 positions · $526.41M reported value (Q2 2026)
  • Top 10 holdings = 99.8% of reported value
  • Largest position: PSNL (PERSONALIS INC) at 35.8%
  • Average position size: $40.49M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a conservative stance, with no new positions added and a hold action on all existing holdings. This suggests a cautious approach to market fluctuations, possibly reflecting uncertainty or a preference for stability in the healthcare sector. 2. Key Moves: There were no additions or deletions in the portfolio, indicating a lack of significant strategic changes. The holdings remained the same as the previous quarter, with no changes in share count or weight. 3. Portfolio Structure: The portfolio is characterized as passive, with a strong sector bias towards healthcare. The fund's risk appetite seems moderate, as indicated by the hold actions and the absence of aggressive moves. 4. Per-Holding One-Liner: - PSNL: Personalis Inc. - A company focused on personalized medicine and diagnostics. - MRNA: Moderna Inc. - A biotechnology company known for mRNA vaccines and therapeutics. - KYMR: Kymera Therapeutics Inc. - A biopharmaceutical company developing treatments for genetic disorders. - AKTS: Akita Therapeutics Inc. - A biotechnology company specializing in novel cancer therapies. - EIKN: Eikon Therapeutics Inc. - A biopharmaceutical company focused on developing treatments for neurological disorders. - TRDA: Entrada Therapeutics Inc. - A biotechnology company focused on developing therapies for rare genetic diseases. - STRO: Sutro Biopharma Inc. - A company developing novel protein therapeutics. - ALEC: Alector Inc. - A biotechnology company focused on treatments for neurodegenerative diseases. - EVAX: Evaxion AS - A biopharmaceutical company specializing in cancer immunotherapy. - VRDN: Viridian Therapeutics Inc. - A biotechnology company focused on developing treatments for rare genetic disorders. 5. One-Sentence Style Summary: The fund maintained a stable, passive healthcare portfolio with a cautious approach, reflecting a preference for steady investments in the biotechnology sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 14.04M $188.20M 35.75%
35.75%
Hold
2 2.31M $161.64M 30.71%
30.71%
Hold
3 772.16K $88.54M 16.82%
16.82%
Hold
4 952.84K $30.71M 5.83%
5.83%
Hold
5 1.67M $21.75M 4.13%
4.13%
Hold
6 1.74M $12.80M 2.43%
2.43%
Hold
7 272.35K $9.04M 1.72%
1.72%
Hold
8 3.55M $7.13M 1.35%
1.35%
Hold
9 1.21M $3.76M 0.71%
0.71%
Hold
10 93.41K $1.72M 0.33%
0.33%
Hold
11 105.98K $1.02M 0.19%
0.19%
Hold
12 19.45K $45.50K 0.01%
0.01%
Hold
13 10.03K $43.82K 0.01%
0.01%
Hold

FAQ

What did Merck & Co., Inc. buy in 2026-Q2?

In its 2026-Q2 13F filing, Merck & Co., Inc. reported 13 equity positions worth $526.41M in aggregate; its largest disclosed positions were PSNL ($188.20M), MRNA ($161.64M), KYMR ($88.54M).

How large is Merck & Co., Inc.'s portfolio?

Merck & Co., Inc. reported $526.41M of long equity holdings across 13 positions as of 2026-Q2. Top-10 holdings account for 99.8% of reported value.

What is Merck & Co., Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/merck-and/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →